PUBLICATIONS

BOOK CHAPTERS

ARTICLES

#Corresponding Authors
    37. Zazueta A, Castillo T, Cavieres Á, González R, Abarca M, Nieto RR, Deneken J, Araneda C, #Moya PR, Bustamante ML (2022) Polymorphisms in schizophrenia-    related genes are potential predictors of antipsychotic treatment resistance and refractoriness. Int J Neuropsychopharmacol. 2022 Apr 13:pyac025. doi:  10.1093/ijnp/pyac025.
    36. Escobar AP, Martínez-Pinto J, Silva-Olivares F, Sotomayor-Zárate R and #Moya PR (2021) Altered grooming syntax and amphetamine-induced dopamine release in EAAT3 overexpressing mice. Frontiers in Cell Neuroscience, 21 June 2021, DOI: 10.3389/fncel.2021.661478.
  1. Spaas J, van Veggel L, Schepers M, Tiane A, van Horssen J, Wilson DM 3rd, Moya PR, Piccart E, Hellings N, Eijnde BO, Derave W, Schreiber R, Vanmierlo T (2021) Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders. Cell Mol Life Sci. 10 Mar 2021. doi: 10.1007/s00018-021-03802-0
  1. Ríos U, Moya PR, Urrejola Ó, Hermosilla J, Gonzalez R, Muñoz P, Moran J, Solervicens P, Jiménez JP (2020) [History of child abuse among patients with bipolar disorders]. Rev Med Chil. 2020 Feb;148(2):204-210. doi: 10.4067/s0034-98872020000200204.
  1. Riquelme-Alcázar J, González-Vargas R, #Moya PR (2020) [ABC transporters and drug resistance in epilepsy: biological plausibility, pharmacogenetics and precision medicine]. Rev Neurol. Jan 1;70(1):23-32. doi: 10.33588/rn.7001.2019188.
  1. Escobar AP, Wendland JR, Chávez AE, #Moya PR (2019) The Neuronal Glutamate Transporter EAAT3 in Obsessive-Compulsive Disorder. Front Pharmacol. Nov 15;10:1362. doi: 10.3389/fphar.2019.01362.
  1. Pérez MÁ, Morales C, Santander O, García F, Gómez I, Peñaloza-Sancho V, Fuentealba P, Dagnino-Subiabre A, Moya PR, Fuenzalida M (2019) Ketamine-Treatment During Late Adolescence Impairs Inhibitory Synaptic Transmission in the Prefrontal Cortex and Working Memory in Adult Rats. Front Cell Neurosci. Aug 20;13:372. doi: 10.3389/fncel.2019.00372.
  1. 30. Cavieres A, Campos-Estrada C, Moya Y, Maldonado R, González-Vargas R, Bustamante ML, #Moya PR (2019) Lack of Association between the IL6R Gene Asp358Ala Variant (rs2228145), IL-6 Plasma Levels, and Treatment Resistance in Chilean Schizophrenic Patients Treated with Clozapine. Schizophr Res Treatment. Jun 25;2019:5601249. doi: 10.1155/2019/5601249
  1. Delgado-Acevedo C, Estay SF, Radke A, Sengupta A, Escobar AP, Henríquez-Belmar F, Reyes C, Haro V, Utreras E, Sotomayor-Zárate R, Cho A, Wendland JR, Kulkarni AB, Holmes A, Murphy DL, Chávez AE, #Moya PR (2019) “Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression” Neuropsychopharmacology May;44(6):1163-1173. doi: 10.1038/s41386-018-0302-7.
  1. Núñez-Vivanco G, Fierro A, Moya P, Iturriaga-Vásquez P, Reyes-Parada M (2018) “3D similarities between the binding sites of monoaminergic target proteins” PLoS One 13(7):e0200637. doi: 10.1371/journal.pone.0200637.
  1. Bonansco C, Martínez-Pinto J, Silva RA, Velásquez VB, Martorell A, Selva MV, Espinosa P, Moya PR, Cruz G, Andrés ME, Sotomayor-Zárate R (2018) “Neonatal exposure to oestradiol increases dopaminergic transmission in nucleus accumbens and morphine-induced conditioned place preference in adult female rats” J Neuroendocrinol; 30(7):e12574. doi: 10.1111/jne.12574.
  1. Moya PR, Wendland JR, Fox MA (2018) “Dennis Luke Murphy, M.D. (1936-2017)”. Genes Brain Behav;17(3):e12455. doi: 10.1111/gbb.12455. 
  1. 25. González LF, Henríquez-Belmar F, Delgado-Acevedo C, Cisternas-Olmedo M, Arriagada G, Sotomayor-Zárate R, Murphy DL, #Moya PR. (2017) “Neurochemical and behavioral characterization of neuronal glutamate transporter EAAT3 heterozygous mice” Res. 19;50(1):29. doi:10.1186/s40659-017-0138-3.
  1. Ahumada C, Bahamondes C, Cerda CA, Silva RA, Cruz G, Moya PR, Sotomayor-Zárate R, Renard GM. (2017) “Amphetamine treatment affects the extra-hypothalamic vasopressinergic system in a sex- and nucleus-dependent manner” J Neuroendocrinol. Feb 24. doi: 10.1111/jne.12465
  1. Muñoz P, Aschrafi A, Moya PR (2016) “Connecting Synaptic Activity with Plasticity-Related Gene Expression: From Molecular Mechanisms to Neurological Disorders,” Neural Plasticity, vol. 2016:7149527. doi: 10.1155/2016/7149527.
  1. Espinosa P, Silva RA, Sanguinetti NK, Venegas FC, Riquelme R, González LF, Cruz G, Renard GM, Moya PR, Sotomayor-Zárate R. (2016) “Programming of Dopaminergic Neurons by Neonatal Sex Hormone Exposure: Effects on Dopamine Content and Tyrosine Hydroxylase Expression in Adult Male Rats” Neural Plasticity. Vol 2016:4569785. oi: 10.1155/2016/4569785.
  1. Sotomayor-Zárate R, Jara P, Araos P, Vinet R, Quiroz G, Renard GM, Espinosa P, Hurtado-Guzmán C, Moya PR, Iturriaga-Vásquez P, Gysling K, Reyes-Parada M (2014) “Improving amphetamine therapeutic selectivity: N,N-dimethyl-MTA has dopaminergic effects and does not produce aortic contraction” Basic Clin Pharmacol Toxicol. 114(5): 395-9. doi: 10.1111/bcpt.12168.
  1. #Moya PR, Wendland JR, Andrews AM, et al. (2013) “Common and rare alleles of the serotonin transporter gene, SLC6A4, associated with Tourette disorder” Movement Disorders. 28(9): 1263-70. doi: 10.1002/mds.25460.
  1. Murphy DL, Moya PR, Fox MA, Rubenstein LM, Wendland JR, Timpano KR (2013) “Anxiety and Affective Disorder Comorbidity Related to Serotonin and other Neurotransmitter Systems: Obsessive-compulsive Disorder (OCD) as an Example of Overlapping Clinical and Genetic Heterogeneity Philosophical Transactions of the Royal Society B: Biological Sciences, 368 (1615); Feb 25. doi: 10.1098/rstb.2012.0435.
  1. #Moya PR, Dodman NH, Timpano KC, Rubenstein L, Rana Z, Fried R, Tischfield JA, et al. (2013) “Neuronal Cadherin (CDH2) Gene Missense Variants in Specific Obsessive-Compulsive Disorder and Tourette Syndrome Phenotypes” European Journal of Human Genetics, 21(8): 850-4. doi: 10.1038/ejhg.2012.245.
  1. #Moya PR, Wendland JR, Salemme J, Fried R, Murphy DL (2013) “miR15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells” International Journal of Neuropsychopharmacology, 16: 621–629. doi: 10.1017/S1461145712000454.
  1. Stewart SE, Mayerfeld C, Arnold PD, Crane JR, O’Dushlaine C, Fagerness JA, Scharf JM, Kassam F, Moya PR, Wendland JR, Delorme R, et al. (2013) “Meta-Analysis of association between obsessive-compulsive disorder and the 3’ region of neuronal glutamate transporter gene SLC1A1” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 162: 367-379. doi: 10.1002/ajmg.b.32137.
  1. Fox MA, Panessiti M, Moya PR, Tolliver TJ, Chen K, Shih JC, Murphy DL (2012) “Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin enhancing drugs: implications for drug side effects in humans” The Pharmacogenomics Journal, 13(6): 551-7. doi: 10.1038/tpj.2012.35.
  1. Sotomayor-Zárate R, Quiroz G, Araya KA, Abarca J, Ibáñez MI, Montecinos A, Guajardo C, Núñez-Vicanco G, Fierro A, Moya PR, Iturriaga-Vásquez P, Gómez-Molina C, Gysling K, Reyes-Parada M (2012) “4-Methylthioamphetamine Increases Dopamine in the Rat Striatum and has Rewarding Effects In Vivo” Basic and Clinical Pharmacology and Toxicology, 111(6):371-9. doi: 10.1111/j.1742-7843.2012.00926.x.
  1. Khaibullina A, Kenyon N, Guptill V, Quezado M, Koziol D, Wesley R, Moya PR, Zhang Z, Saha A, Mukherjee AB, Quezado ZMN (2012) “In a model of Batten disease, palmitoyl protein thioesterase-1 deficiency is associated with brown adipose tissue and thermoregulation abnormalities” PLoS One, 7(11):e48733. doi: 10.1371/journal.pone.0048733
  1. Liu X, Cannon DM, Akula N, Moya PR, Knudsen GM, Arentzen TE, Steele J, Laje G, Drevets WC, McMahon FJ (2011) “A non-synonymous polymorphism in galactose mutarotase (GALM) is associated with serotonin transporter binding potential in the human thalamus: results of a genome-wide association study” Molecular Psychiatry 16(6):584-5. doi: 10.1038/mp.2011.1.
  1. Murphy DL and Moya PR (2011) “Human Serotonin Transporter Gene (SLC6A4) variants: Their contributions to understanding pharmacogenomic and other functional GxG and GxE differences in health and disease” Current Opinions in Pharmacology, 11(1):3-10. doi: 10.1016/j.coph.2011.02.008.
  1. #Moya PR, Jensen CL, Fox MA, French H, Wendland JR and Murphy DL (2011) “Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice” BMC (BioMed Central) Pharmacology 11:3. doi: 10.1186/1471-2210-11-3.
  1. #Moya PR, Murphy DL, McMahon FJ and Wendland JR (2010) “Increased gene expression of Diacylglycerol Kinase Eta in Bipolar Disorder” International Journal of Neuropsychopharmacology 13(8):1127-1128. doi: 10.1017/S1461145710000593.
  1. Omata N, Chiu CT, Moya PR, Leng Y, Chiu C, Wang Z, Hunsberger J, Leeds P, Chuang DM (2011) “Lentivirally mediated GSK-3β silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice ” International Journal of Neuropsychopharmacology 14(5):711-717. doi: 10.1017/S1461145710000726.
  1. Wendland JR, Moya PR, Timpano K, Anavitarte A, Kruse M, Wheaton M, Ren-Patterson R, Murphy DL (2009) “A haplotype containing quantitative trait loci for SLC1A1 gene expression is associated with obsessive-compulsive disorder” Archives of General Psychiatry 66(4):408-16. doi: 10.1001/archgenpsychiatry.2009.6.
  1. (*co-first author) Wendland JR*, Moya PR*, Kruse MR, Ren-Patterson RF, Jensen CL, Timpano KR and Murphy DL (2008) “A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder” Human Molecular Genetics 17(5):717-23. doi: 10.1093/hmg/ddm343.
  1. Murphy, DL, Fox MA, Timpano KR, Moya PR, Ren-Patterson R, Andrews A, Holmes, A, Wendland JR, Lesch KP (2008) “How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, whose functions influence the entire serotonin system” Neuropharmacology 55:932-960. doi: 10.1016/j.neuropharm.2008.08.034.
  1. Gobbi M, Funicello M, Gerstbrein K, Holy M, Moya PR, Sotomayor R, Forray MI, Gysling K, Paluzzi S, Bonanno G, Reyes-Parada M, Sitte HH, Mennini T (2008) “N,N-dimethyl-thioamphetamine and methylthio-amphetamine, two non-neurotoxic substrates of 5-HT transporters, have scant in vitro efficacy for the induction of transporter-mediated 5-HT release and currents” Journal of Neurochemistry 105(5):1770-80. doi: 10.1111/j.1471-4159.2008.05272.x.
  1. Moya PR, Berg KA, Gutierrez-Hernandez MA, Saez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP (2007) “Functional Selectivity of Hallucinogenic Phenethylamine and Phenylisopropylamine Derivatives at Human 5-HT2A and 5-HT2C Receptors” Journal of Pharmacology and Experimental Therapeutics 321(3):1054-61. doi: 10.1124/jpet.106.117507
  1. Valdecantos P, Briones R, Moya P, Germain A, and Huidobro-Toro JP (2003) “Pharmacological identification of P2X(1), P2X(4) and P2X(7) nucleotide receptors in the smooth muscles of human umbilical cord and chorionic blood vessels” Placenta 24(1):17-26. DOI: 10.1053/plac.2002.0862
  1. Acuña-Castillo C, Villalobos C, Moya PR, Sáez P, Cassels BK, and Huidobro-Toro JP (2002) “Differences in potency and efficacy of a series of phenylisopropylamine / phenylethylamine pairs at 5-HT2A and 5-HT2C receptors” British Journal of Pharmacology 136: 510-519. doi: 10.1038/sj.bjp.0704747.

  • Murphy DL, Moya PR, Wendland JR and Timpano KR (2012)“Genetic contributions to obsessive-compulsive disorder (OCD) and OCD-related disorders”, en Principles of Psychiatric Genetics, J. Nurnberger & W. Berrettini Eds, Cambridge University Press, Cambridge, UK. Capitulo 11, pp 121-133. ISBN: 0521896495

.